Praxis Precision Medicines Files 8-K for 'Other Event'

TL;DR

**Praxis filed an 8-K for an 'Other Event' on Jan 11, check for big news.**

AI Summary

Praxis Precision Medicines, Inc. filed an 8-K on January 11, 2024, to report an "Other Event" and include "Financial Statements and Exhibits." This filing indicates that the company is likely providing an update on a significant development, potentially related to its financial position or a corporate action, which could impact its stock price. Investors should pay close attention to the specific details within the full filing to understand the nature of this event and its potential implications for the company's future performance and stock value.

Why It Matters

This filing signals a potentially important, undisclosed event that could affect Praxis Precision Medicines' operations or financial health. Investors need to review the full filing to understand the specific details and assess any impact on their investment.

Risk Assessment

Risk Level: medium — The 'Other Event' designation in an 8-K can cover a wide range of significant developments, making the specific impact unknown without further details, thus posing a medium risk.

Analyst Insight

A smart investor would immediately seek out the full 8-K filing to understand the specific details of the 'Other Event' and 'Financial Statements and Exhibits' to assess its potential impact on Praxis Precision Medicines, Inc. before making any trading decisions.

Key Players & Entities

• Praxis Precision Medicines, Inc. (company) — the registrant filing the 8-K
• January 11, 2024 (date) — date of earliest event reported
• 001-39620 (other) — Commission File Number
• PRAX (other) — Trade Symbol for Common Stock
• The Nasdaq Global Select Market (other) — exchange where Common Stock is registered

FAQ

Key Financial Figures

• $0.0001 — e on which registered Common Stock, $0.0001 par value per share PRAX The Nasdaq
• $35.50 — ng price of the Shares to the public is $35.50 per share, and the offering price of th
• $35.4999 — he Pre-funded Warrants to the public is $35.4999 per underlying share, which equals the
• $0 — tock being sold in this Offering, minus $0.0001, the Pre-funded Warrants' exercise
• $161.7 m — fering are expected to be approximately $161.7 million, after deducting underwriting dis

Filing Documents

• tm243213d1_8k.htm (8-K) — 38KB
• tm243213d1_ex1-1.htm (EX-1.1) — 251KB
• tm243213d1_ex4-1.htm (EX-4.1) — 73KB
• tm243213d1_ex5-1.htm (EX-5.1) — 21KB
• tm243213d1_ex5-1img01.jpg (GRAPHIC) — 4KB
• tm243213d1_ex5-1img02.jpg (GRAPHIC) — 4KB
• 0001104659-24-003764.txt ( ) — 653KB
• prax-20240111.xsd (EX-101.SCH) — 3KB
• prax-20240111_lab.xml (EX-101.LAB) — 33KB
• prax-20240111_pre.xml (EX-101.PRE) — 22KB
• tm243213d1_8k_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. On January 11, 2024, Praxis Precision Medicines, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Piper Sandler & Co. and Truist Securities, Inc., as representatives of the several underwriters named in Schedule A thereto (collectively, the "Underwriters"), relating to an underwritten offering of 3,168,275 shares (the "Shares") of the Company's common stock, $0.0001 par value per share (the "Common Stock"), and, in lieu of Common Stock to certain investors, pre-funded warrants (the "Pre-funded Warrants") to purchase up to 1,056,725 shares of Common Stock (the "Offering"). The closing of the Offering is expected to take place on January 16, 2024, subject to the satisfaction of customary closing conditions. All of the Shares and the Pre-funded Warrants are being sold by the Company. The offering price of the Shares to the public is $35.50 per share, and the offering price of the Pre-funded Warrants to the public is $35.4999 per underlying share, which equals the price per share of Common Stock being sold in this Offering, minus $0.0001, the Pre-funded Warrants' exercise price per share. The Company also granted the underwriters an option to purchase up to 633,750 additional shares of Common Stock within 30 days from the date of the Underwriting Agreement. On January 12, 2024, the underwriters exercised the option to purchase such additional shares in full. The net proceeds from the Offering are expected to be approximately $161.7 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, and giving effect to the exercise of the underwriters' option to purchase additional shares. The Company does not intend to list the Pre-funded Warrants on The Nasdaq Global Select Market ("Nasdaq") or any other nationally recognized securities exchange or trading system. The exercise price and the number of shares of Common Stock issuable upon exercis

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the closing of the Offering, the Company's intent not to list the Pre-funded Warrants on Nasdaq or any other nationally recognized securities exchange or trading system, anticipated amount of net proceeds from the Offering, the intended use of such proceeds, and the sufficiency of the net proceeds from the Offering and existing cash and cash equivalents to fund operating expenses and capital expenditure requirements. The forward-looking statements included in this Current Report on Form 8-K are subject to a number of risks, uncertainties and assumptions, including, without limitation, risks and uncertainties associated with market conditions, the satisfaction of customary closing conditions related to the offering and other risks as described in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, its Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. These statements are based only on facts currently known by the Company and speak only as of the date of this Current Report on Form 8-K. As a result, you are cautioned not to rely on these forward-looking statements and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 1.1 Underwriting Agreement, dated January 11, 2024, by and among Praxis Precision Medicines, Inc. and Piper Sandler & Co. and Truist Securities, Inc., as representatives of the several underwriters named therein. 4.1 Form of Pre-funded Warrant. 5.1 Opinion of Latham & Watkins LLP. 23.1 Consent of Latham & Watkins LLP (included in Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PRAXIS PRECISION MEDICINES, INC. Date: January 12, 2024 By: /s/ Marcio Souza Marcio Souza Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR